Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity

The NETTER-1 trial demonstrated significantly improved progression-free survival (PFS) for peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors (NET) emphasizing the high demand for response prediction in appropriate candidates. In this multicenter study, we aimed to elucidate the p...

Descripción completa

Detalles Bibliográficos
Autores principales: Werner, Rudolf A., Lapa, Constantin, Ilhan, Harun, Higuchi, Takahiro, Buck, Andreas K., Lehner, Sebastian, Bartenstein, Peter, Bengel, Frank, Schatka, Imke, Muegge, Dirk O., Papp, László, Zsótér, Norbert, Große-Ophoff, Tobias, Essler, Markus, Bundschuh, Ralph A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351689/
https://www.ncbi.nlm.nih.gov/pubmed/27705948
http://dx.doi.org/10.18632/oncotarget.12402

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351689/
https://www.ncbi.nlm.nih.gov/pubmed/27705948
http://dx.doi.org/10.18632/oncotarget.12402

Ejemplares similares